Garrison Point Advisors LLC Sells 700 Shares of Becton, Dickinson and Company (NYSE:BDX)

Garrison Point Advisors LLC lessened its holdings in Becton, Dickinson and Company (NYSE:BDX) by 38.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,125 shares of the medical instruments supplier’s stock after selling 700 shares during the period. Garrison Point Advisors LLC’s holdings in Becton, Dickinson and Company were worth $271,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of BDX. WR Wealth Planners LLC grew its stake in Becton, Dickinson and Company by 1.4% in the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock valued at $696,000 after purchasing an additional 42 shares during the period. Clear Creek Financial Management LLC grew its position in Becton, Dickinson and Company by 5.1% during the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after buying an additional 44 shares during the period. Sound Income Strategies LLC increased its holdings in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the last quarter. Central Pacific Bank Trust Division raised its position in Becton, Dickinson and Company by 22.5% in the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after acquiring an additional 45 shares during the period. Finally, Capital Advisors Ltd. LLC boosted its stake in Becton, Dickinson and Company by 3.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock valued at $326,000 after acquiring an additional 48 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.8 %

NYSE BDX opened at $238.62 on Friday. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The stock’s 50-day simple moving average is $237.33 and its two-hundred day simple moving average is $235.16. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $262.23. The company has a market capitalization of $68.96 billion, a price-to-earnings ratio of 52.56, a PEG ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. The business had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.96 earnings per share. Research analysts forecast that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Analyst Ratings Changes

BDX has been the subject of several research analyst reports. Evercore ISI raised their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Raymond James decreased their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, Stifel Nicolaus boosted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.